Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry

Antiviral Chemistry and Chemotherapy

Volumn 14, Issue 6, 2003, Pages 321-328

  Witvrouw, Myriam ^a   Pannecouque, Christophe ^a   Fikkert, Valery ^a   Hantson, Anke ^a   Van Remoortel, Barbara ^a   Hezareh, Marjan ^b   De Clercq, Erik ^a   Brown, Stephen J ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b AIDS Research Alliance   (United States)

Author keywords

Entry inhibitor; HIV; Prostratin; SIV

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DEXTRAN SULFATE; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; NEVIRAPINE; PHORBOL ESTER; POLYANION; PROSTRATIN; PROTEINASE INHIBITOR; QUATERNARY AMMONIUM DERIVATIVE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; EXPERIMENT; GENE MUTATION; GENETIC RECOMBINATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ADSORPTION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

EID: 0842349133     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020301400604     Document Type: Article

References (23)

1. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, & Martin MA (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. Journal of Virology 59:284-291.
2. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W & Montagnier L (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-871.
3. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA & Fauci AS (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences, USA 94:13193-13197.
4. Daniel MD, Letvin NL, Sehgal PK, Hunsmann G, Schmidt DK, King NW & Desrosiers RC (1987) Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. Journal of General Virology 68:3183-3189.
5. De Vreese K, Kofler-Mongold V, Leutgeb C, Weber V, Vermeire K, Schacht S, Anné J, De Clercq E, Datema R & WG Werner (1996) The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. Journal of Virology 70:689-696.
6. Este JA, Schols D, De Vreese K, Van Laethem K, Vandamme AM, Desmyter J & De Clercq E (1997) Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Molecular Pharmacology 52:98-104.
7. Fikkert V, Cherepanov P, Van Laethem K, Hantson A, Van Remoortel B, Pannecouque C, De Clercq E, Debyser Z, Vandamme AM & Witvrouw M (2002). Chimeric Virus Technology (CVT) for HIV env-genes to evaluate the resistance/susceptibility profile towards HIV entry inhibitors. Antimicrobial Agents & Chemotherapy 46:3954-3962.
8. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD & Siliciano RH (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [see comments]. Science 278:1295-1300.
9. Gulakowski RJ, McMahon JB, Buckheit Jr RW, Gustafson KR & Boyd MR (1997) Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Research 33:87-97.
10. Gustafson KR, Cardellina JH, McMahon II JB, Gulakowski RJ, Ishitoya J, Szallasi Z, Lewin NE, Blumberg PM, Weislow OS & Beutler JA (1992) A nonpromoting phorbol from the Samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. Journal of Medicinal Chemistry 35:1978-1986.
11. Korin YD, Brooks DG, Brown S, Korotzer A & Zack JA (2002) Effects of prostratin on T-cell activation and human immunodeficiency virus latency. Journal of Virology 76:8118-8123.
12. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J & De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods 20:309-321.
13. Pluymers W, Neamati N, Pannecouque C, Fikkert V, Marchand C, Burke Jr TR, Pommier Y, Schols D, De Clercq E, Debyser Z & Witvrouw M (2000) Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Molecular Pharmacology 58:641-648.
14. Popovic M, Sarngadharan MG, Read E & Gallo RC (1984) Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
15. Rey MA, Krust B, Laurent AG, Guetard D, Montagnier L & Hovanessian AG (1989) Characterization of an HIV-2-related virus with a smaller sized extracellular envelope glycoprotein. Virology 173:258-267.
16. Saag MS & Schooley RT (1998) Antiretroviral chemotherapy. Current Clinical Topics in Infectious Diseases 18:154-179.
17. Schmit JC, Cogniaux J, Hermans P, Van Vaeck C, Sprecher S, Van Remoortel B, Witvrouw M, Balzarini J, Desmyter J, De Clercq E & Vandamme AM (1996). Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. Journal of Infectious Diseases 174:962-968.
18. Spire B, Sire J, Zachar V, Rey F, Barre-Sinoussi F, Galibert F, Hampe A & Chermann JC (1989) Nucleotide sequence of HIV1-NDK: a highly cytopathic strain of the human immunodeficiency virus. Gene 81:275-284.
19. Szallasi Z & Blumberg PM (1991) Prostratin, a nonpromoting phorbol ester, inhibits induction by phorbol 12-myristate 13-acetate of ornithine decarboxylase, edema, and hyperplasia in CD-1 mouse skin. Cancer Research 51:5355-5360.
20. Szallasi Z, Krausz KW & Blumberg PM (1992) Non-promoting 12-deoxyphorbol 13-esters as potent inhibitors of phorbol 12-myristate 13-acetate-induced acute and chronic biological responses in CD-1 mouse skin. Carcinogenesis 13:2161-2167.
21. Szallasi Z, Krsmanovic L & Blumberg PM (1993) Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin. Cancer Research 53:2507-2512.
22. Witvrouw M, Fikkert V, Pluymers W, Matthews B, Mardel K, Schols D, Raff J, Debyser Z, De Clercq E, Holan G & Pannecouque C (2000) Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Molecular Pharmacology 58:1100-1108.
23. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA & DD Richman DD (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.